Lexicon Pharmaceuticals Культура компании

Dr. Pablo Lapuerta, M.D. has been the Chief Medical Officer and Executive Vice President of Lexicon Pharmaceuticals, Inc., since March 2011 and February 2015 respectively. Dr. Lapuerta served as Executive Vice President of Safety & Pharmacovigilance and Executive Vice President of Clinical Development at Lexicon Pharmaceuticals, Inc. from August, 2014 to February 2015 and since February 2013 until August 2014 respectively. Dr. Lapuerta has over 11 years of experience in the pharmaceutical industry. Dr. Lapuerta served as Chief Medical Officer and Senior Vice President of Clinical Strategy of Cogentus Pharmaceuticals Inc. He served as Senior Vice President of Clinical Development at Lexicon Pharmaceuticals, Inc. from March 2011 to February 2013. Prior to joining Cogentus, he served as an Executive Director of Global Medical Affairs at Bristol-Myers Squibb. At Bristol-Myers Squibb, Dr. Lapuerta also designed and executed clinical trials and was responsible for supplemental new drug applications to regulatory agencies in several countries. Dr. Lapuerta was responsible for all global medical affairs activities for all Bristol-Myers Squibb products in the areas of hypertension, diabetes and obesity. He led a clinical program for expanded use of irbesartan/HCTZ received unanimous support from the FDA Cardiorenal Advisory Committee. He also served as Clinical Assistant Professor at Robert Wood Johnson Medical School in the department of internal medicine. Previously, he served as an Assistant Professor of Internal Medicine at the University of Southern California and provided consulting for the RAND Institute. He taught internal medicine and cared for patients. Dr. Lapuerta is a B.A graduate from Harvard College and an M.D. from Harvard Medical School. He conducted his residency in internal medicine at the University of North Carolina at Chapel Hill.

Dr. Praveen Tyle, Ph.D. has been Executive Vice President of Research and Development at Lexicon Pharmaceuticals, Inc. since May 16, 2016. Dr. Tyle serves as Member of Executive Board at Rapid Pharmaceuticals AG. He joined Lexicon with more than 30 years of pharmaceutical industry experience of advancing new medical device and drug candidate pipelines to commercial success. He led and completed the successful merger of Vertical Pharmaceuticals and Trigen Laboratories with Osmotica Holdings in February 2016. He served as the Chief Executive Officer and President of Osmotica Pharmaceutical Corp. since January 2013 until 2016. He served as the Chief Scientific Officer and Executive Vice President of Osmotica Pharmaceutical Corp. from October 15, 2012 to January 2013. He served as President and Chief Executive Officer of Osmotica Holdings. He served as Senior Advisor at Arsenal Capital Partners, Inc. He served as the Chief Science Officer of The United States Pharmacopeial Convention, Inc. since November 2011. He served as Executive Vice President of the United States Pharmacopeia. Dr. Tyle served as the Chief Scientific Officer and Senior Vice President of Research & Development of Bausch & Lomb Incorporated. since July 19, 2004. Dr. Tyle focused in areas including vision care (lens and lens care), pharmaceuticals (prescription, OTC, generics, nutritionals), and surgical (refractive and cataract). He is also responsible for all of Bausch & Lomb's preclinical development programs, product development efforts and clinical, medical and regulatory affairs and quality assurance. Dr. Tyle joined Bausch & Lomb from Valeant Pharmaceuticals International, Inc. (also known as Biovail Corporation), where he served as Group Vice President of Pharmaceutical Sciences and Manufacturing since June 5, 2003. Dr. Tyle has 30 years of drug development and commercialization experience. He worked nearly four years at Pharmacia Corporation, where he served as Vice President and Global Head of Pharmaceutical Sciences. He served as Senior Vice President & Global Head of Research & Development and business development and licensing Novartis OTC. Dr. Tyle began his professional career as a formulations research chemist in drug delivery research with American Cynamid Company (now Wyeth), moving on to executive leadership and scientific positions with Sandoz Pharmaceuticals (now Novartis), Agouron Pharmaceuticals (now Pfizer) and Aronex Pharmaceuticals (now Antigenics). Since 1999, he served as Vice President of Pharmaceutical sciences at U.S., Pharmacia & Upjohn (now Pfizer). Dr. Tyle has been a Director of Eyegate Pharmaceuticals, Inc. since June 2008. He serves as an Independent Director of Orient Europharma Co., Ltd., Taiwan and Interpath Pharmaceuticals, Houston. He serves as Director of GrayBug, LLC and Yolia Health. Dr. Tyle has been a Member of Scientific Advisory Board at Vioquest Pharmaceuticals Inc. since August 1, 2006. He serves as Member of the Council of Healthcare Advisors, the advisory board of Oakland University Center for Biomedical Research and is a Scientific Advisor to CB Health Ventures of Boston and Epimmune Inc., of San Diego. He served as a Member of Scientific Advisory Board of Vela Pharmaceuticals Inc. He served as a Board Member of Osmotica Holdings. He served as a Director of Osmotica Pharmaceutical Corp. since January 2013 until 2016. Dr. Tyle serves as adjunct professor at Howard University and the University of Rochester Medical Center. He holds academician appointments as an Adjunct Professor of Pharmacy at the University of Rhode Island and at the University of Houston, Texas. He is Editor of seven books about drug development, holds several patents and is author of more than 130 technical and scientific papers and presentations. He received the Distinguished Alumni award from the Institute of Technology, Banaras Hindu University. Dr. Tyle has been honored as a distinguished research fellow by the Shandong Pharmaceutical Research Institute, China. Dr. Tyle received a Ph.D. degree in Pharmaceutics and Pharmaceutical Chemistry from the Ohio State University in 1984 and a Bachelor of Pharmacy degree the Indian Institute of Technology, Banaras Hindu University in India in 1980.

Dr. Alan J. Main, Ph.D. has been an Executive Vice President of Commercial Supply Operations at Lexicon Pharmaceuticals, Inc. since May 15, 2017 and served as its Executive Vice President of CMC and Supply Operations since February 2015 until May 15, 2017. Dr. Main served as an Executive Vice President of Pharmaceutical Research at Lexicon Pharmaceuticals Inc. from February 26, 2007 to February, 2015. Dr. Main served as Senior Vice President of Lexicon Pharmaceuticals Inc. from July 2001 to February 26, 2007. He served as President, Chief Executive Officer and Director of Coelacanth Chemical Corporation from January 2000 until Lexicon Pharmaceuticals Inc.'s acquisition of Coelacanth in July 2001. Before joining Coelacanth, he served as Senior Vice President, U.S. Research at Novartis Pharmaceuticals Corporation, where he worked for 20 years. He served as Director of Myriad Genetics Inc. Dr. Main holds a B.S. from the University of Aberdeen, Scotland and Ph.D. in Organic Chemistry from the University of Liverpool, England and completed postdoctoral studies at the Woodward Research Institute.

Mr. Jeffrey L. Wade, J.D. has been the Chief Financial Officer and Executive Vice President of Corporate & Administrative Affairs of Lexicon Genetics Inc., (also known as Lexicon Pharmaceuticals, Inc) since May 2010 and February 2015 respectively. Mr. Wade served as an Executive Vice President of Corporate Development at Lexicon Pharmaceuticals, Inc., from May 2010 to February 2015. Mr. Wade served as an Executive Vice President and General Counsel of Lexicon Genetics Inc. since February 2000 and also served as its Secretary. He served as Senior Vice President and Chief Financial Officer of Lexicon Genetics Inc. from January 1999 to February 2000. From 1988 through December 1998, he was a corporate securities and finance attorney with the law firm of Andrews & Kurth L.L.P., for the last two years as a partner, where he represented companies in the biotechnology, information technology and energy industries. Mr. Wade is a member of the boards of Directors of the Texas Healthcare and Bioscience Institute and the Texas Life Sciences Foundation. He received his B.A. and J.D. from The University of Texas.

Jeffrey Wade serves as the Executive Vice President, Corporate and Administrative Affairs and CFO of Lexicon Pharmaceuticals, Inc.. Jeffrey started at Lexicon Pharmaceuticals, Inc. in Jan of 1999. Jeffrey currently resides in the Houston, Texas Area.

Praveen Tyle serves as the Executive Vice President, Research & Development of Lexicon Pharmaceuticals, Inc.. Praveen started at Lexicon Pharmaceuticals, Inc. in May of 2016. Praveen currently resides in the Houston, Texas Area.

Pablo Lapuerta serves as the Executive Vice President and Chief Medical Officer of Lexicon Pharmaceuticals, Inc.. Pablo started at Lexicon Pharmaceuticals, Inc. in Mar of 2013. Pablo currently resides in the Greater New York City Area.